AbbVie to Make $18 Million Milestone Payment to EvolveImmune Therapeutics After Nomination of Development Candidate


Idag, 16:11

10:11 AM EDT, 04/28/2026 (MT Newswires) -- AbbVie (ABBV) partner EvolveImmune Therapeutics has nominated a development candidate for a next-generation cancer biotherapeutic, triggering a preclinical milestone payment of $18 million from AbbVie, the immuno-oncology company said Tuesday.

The two companies entered into a collaboration and option-to-license agreement to develop multi-specific biologics for multiple targets in oncology in October 2024, according to a statement.

Price: 198.10, Change: +0.72, Percent Change: +0.37

Ämnen i artikeln

AbbVie

Senast

169,80

1 dag %

−0,18%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån